FOE vs. VSM: Which Stock Should Value Investors Buy Now?
Agenus Inc. AGEN is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been mixed so far. The company has surpassed estimates thrice in the trailing four quarters and missed the same on one occasion, bringing the average positive surprise to 15.99%.
Currently, Agenus has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported a loss of 35 cents in the fourth quarter of 2017 which was wider than both the consensus loss estimate of 28 cents per share, and a loss of 30 cents reported a year ago.
Revenue: Revenues missed expectations in the quarter. Agenus posted revenues of $8.4 million, compared to our consensus estimate of $16 million.
Share Price Impact: Shares fell 3.9% in pre-market trading.
Check back later for our full write up on AGEN earnings report later!
Agenus Inc. Price and EPS Surprise
Agenus Inc. Price and EPS Surprise | Agenus Inc. Quote
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others. Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research